Ocrevus (ocrelizumab) for the Treatment of Multiple Sclerosis

Ocrevus (ocrelizumab), developed by Genentech, a member of Roche Group, is indicated for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis.

Source: Drug Development Technology - October 6, 2016 Category: Pharmaceuticals Source Type: news